Literature DB >> 6961402

Circular dichroism spectroscopy of heparin-antithrombin interactions.

A L Stone, D Beeler, G Oosta, R D Rosenberg.   

Abstract

We have utilized circular dichroism spectroscopy to examine the interaction of antithrombin with heparin-derived oligosaccharides and mucopolysaccharides of various sizes. Our studies demonstrate that the various complexes exhibit two major types of chiral absorption spectra. The first of these patterns is seen when octasaccharide, decasaccharide, dodecasaccharide, or tetradecasaccharide fragments bind to the protease inhibitor. The circular dichroism spectra of these complexes when compared to the spectrum of free antithrombin show several distinguishing characteristics. On the one hand, there is a marked general increase in positive chiral absorption that is maximal at 296 and 288 nm and 290 and 282.5 nm. These observations indicate perturbation of "buried" and "exposed" tryptophan residues. On the other hand, a significant augmentation in circular dichroism that peaks at 269.5 and 263 nm is noted. These findings are probably due to the summed positive and negative contributions arising from tryptophan residue(s), disulfide bridge(s), and phenylalanine residue(s). Given that these heparin fragments are able to accelerate factor Xa-antithrombin interactions but not thrombin-antithrombin interactions, the above spectral transitions must be associated with either the binding of a critical domain of the oligosaccharides to the protease inhibitor or the "activation" of the protease inhibitor with respect to factor Xa neutralization. The second of these patterns is apparent when octadecasaccharide, low molecular weight heparin (6,500), and high molecular weight heparin (22,000) interact with antithrombin. The circular dichroism spectra of these complexes compared to the spectrum of free protease inhibitor are similar to the first pattern except for changes within the 292- to 282-nm and 275- to 255-nm regions. The subtraction of the first pattern from the second pattern reveals a shallow negative band between 300 and 275 nm with potential negative minima at 290 and 283 nm as well as a deep negative band between 275 and 255 nm with possible negative minima at 268 and 262 nm. This chiral absorption profile is most likely to arise from conformational changes of a disulfide bridge(s). However, we cannot completely exclude the possibility that the above circular dichroism difference curve might be explained on the basis of transitions originating from a tryptophan residue(s). Given our method for generating the above data, these spectral alterations must be associated with the binding of a second critical domain of the mucopolysaccharide to antithrombin that is required for rapid complex formation with thrombin or the activation of the protease inhibitor with respect to the neutralization of the latter enzyme.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6961402      PMCID: PMC347304          DOI: 10.1073/pnas.79.23.7190

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  The separation of active and inactive forms of heparin.

Authors:  L H Lam; J E Silbert; R D Rosenberg
Journal:  Biochem Biophys Res Commun       Date:  1976-03-22       Impact factor: 3.575

2.  Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin.

Authors:  M Höök; I Björk; J Hopwood; U Lindahl
Journal:  FEBS Lett       Date:  1976-07-01       Impact factor: 4.124

Review 3.  Aromatic contributions to circular dichroism spectra of proteins.

Authors:  E H Strickland
Journal:  CRC Crit Rev Biochem       Date:  1974-01

4.  The purification and mechanism of action of human antithrombin-heparin cofactor.

Authors:  R D Rosenberg; P S Damus
Journal:  J Biol Chem       Date:  1973-09-25       Impact factor: 5.157

5.  Fine structure in the near-ultraviolet circular dichroism and absorption spectra of tryptophan derivatives and chymotrypsinogen A at 77 degrees K.

Authors:  E H Strickland; J Horwitz; C Billups
Journal:  Biochemistry       Date:  1969-08       Impact factor: 3.162

6.  Evidence for a heparin-induced conformational change on antithrombin III.

Authors:  G B Villaneuva; I Danishefsky
Journal:  Biochem Biophys Res Commun       Date:  1977-01-24       Impact factor: 3.575

7.  Binding of low-affinity and high-affinity heparin to antithrombin. Ultraviolet difference spectroscopy and circular dichroism studies.

Authors:  B Nordenman; I Björk
Journal:  Biochemistry       Date:  1978-08-08       Impact factor: 3.162

8.  Fractionation of low molecular weight heparin species and their interaction with antithrombin.

Authors:  D Beeler; R Rosenberg; R Jordan
Journal:  J Biol Chem       Date:  1979-04-25       Impact factor: 5.157

9.  Structure-function relationships of heparin species.

Authors:  R D Rosenberg; G Armand; L Lam
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

10.  The size and shape of human and bovine antithrombin III.

Authors:  B Nordenman; C Nyström; I Björk
Journal:  Eur J Biochem       Date:  1977-08-15
View more
  10 in total

1.  Cell mutants defective in synthesizing a heparan sulfate proteoglycan with regions of defined monosaccharide sequence.

Authors:  A L De Agostini; H K Lau; C Leone; H Youssoufian; R D Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Multiple mechanisms for exogenous heparin modulation of vascular endothelial growth factor activity.

Authors:  Errol Wijelath; Mayumi Namekata; Jacqueline Murray; Mai Furuyashiki; Siyuan Zhang; Daniel Coan; Masahiro Wakao; Robert B Harris; Yasuo Suda; Lianchun Wang; Michael Sobel
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

Review 3.  The haemostatic function of the vascular endothelial cell.

Authors:  H A Bull; S J Machin
Journal:  Blut       Date:  1987-08

Review 4.  Natural anticoagulant mechanisms.

Authors:  R D Rosenberg; J S Rosenberg
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

5.  Expression of functionally active human antithrombin III.

Authors:  A W Stephens; A Siddiqui; C H Hirs
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

6.  Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.

Authors:  D A Lane; J Denton; A M Flynn; L Thunberg; U Lindahl
Journal:  Biochem J       Date:  1984-03-15       Impact factor: 3.857

7.  The relative molecular mass dependence of the anti-factor Xa properties of heparin.

Authors:  V Ellis; M F Scully; V V Kakkar
Journal:  Biochem J       Date:  1986-09-01       Impact factor: 3.857

8.  The allosteric mechanism of activation of antithrombin as an inhibitor of factor IXa and factor Xa: heparin-independent full activation through mutations adjacent to helix D.

Authors:  Alexey Dementiev; Richard Swanson; Ryan Roth; Giulia Isetti; Gonzalo Izaguirre; Steven T Olson; Peter G W Gettins
Journal:  J Biol Chem       Date:  2013-09-25       Impact factor: 5.157

9.  Effect of a heparan sulphate with high affinity for antithrombin III upon inactivation of thrombin and coagulation factor Xa.

Authors:  M F Scully; V Ellis; N Shah; V Kakkar
Journal:  Biochem J       Date:  1989-09-01       Impact factor: 3.857

10.  Biological implications of the structural, antithrombin affinity and anticoagulant activity relationships among vertebrate heparins and heparan sulphates.

Authors:  P Hovingh; M Piepkorn; A Linker
Journal:  Biochem J       Date:  1986-07-15       Impact factor: 3.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.